KR101567885B1 - 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물 - Google Patents

고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR101567885B1
KR101567885B1 KR1020137026784A KR20137026784A KR101567885B1 KR 101567885 B1 KR101567885 B1 KR 101567885B1 KR 1020137026784 A KR1020137026784 A KR 1020137026784A KR 20137026784 A KR20137026784 A KR 20137026784A KR 101567885 B1 KR101567885 B1 KR 101567885B1
Authority
KR
South Korea
Prior art keywords
hyperlipidemia
gout
uric acid
patient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137026784A
Other languages
English (en)
Korean (ko)
Other versions
KR20140019795A (ko
Inventor
만층 쉐리 쿠
치-쾅 천
웨이-수 루
이-인 린
Original Assignee
티더블유아이 바이오테크놀로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티더블유아이 바이오테크놀로지 인코포레이티드 filed Critical 티더블유아이 바이오테크놀로지 인코포레이티드
Publication of KR20140019795A publication Critical patent/KR20140019795A/ko
Application granted granted Critical
Publication of KR101567885B1 publication Critical patent/KR101567885B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137026784A 2011-03-11 2012-03-07 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물 Expired - Fee Related KR101567885B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11
US61/451,600 2011-03-11
PCT/US2012/027993 WO2012125359A1 (en) 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Publications (2)

Publication Number Publication Date
KR20140019795A KR20140019795A (ko) 2014-02-17
KR101567885B1 true KR101567885B1 (ko) 2015-11-10

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137026784A Expired - Fee Related KR101567885B1 (ko) 2011-03-11 2012-03-07 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물

Country Status (16)

Country Link
US (1) US8865689B2 (enExample)
EP (1) EP2683372B1 (enExample)
JP (1) JP6012639B2 (enExample)
KR (1) KR101567885B1 (enExample)
CN (1) CN103429236B (enExample)
AR (1) AR085662A1 (enExample)
AU (1) AU2012229443B2 (enExample)
BR (1) BR112013022332A2 (enExample)
CA (1) CA2829101C (enExample)
ES (1) ES2634562T3 (enExample)
IL (1) IL228030B (enExample)
MX (1) MX350666B (enExample)
PT (1) PT2683372T (enExample)
RU (1) RU2603050C2 (enExample)
TW (1) TWI505827B (enExample)
WO (1) WO2012125359A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709754B2 (en) 2016-04-08 2020-07-14 Korea Institute Of Oriental Medicine Composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising extract of Alpinia oxyphylla as effective ingredient

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794566C (en) * 2010-04-08 2018-06-12 Twi Biotechnology, Inc. Methods of using diacerein as an adjunctive therapy for diabetes
MX350666B (es) 2011-03-11 2017-09-12 Twi Biotechnology Inc Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技（武汉）有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
RU2690372C2 (ru) * 2015-04-20 2019-06-03 Тви Биотекнолоджи, Инк. Лекарственные средства, содержащие диацереин, и способы снижения уровней мочевой кислоты в крови с его использованием
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
WO2017004319A1 (en) 2015-07-01 2017-01-05 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
BR112018003212A2 (pt) * 2015-08-17 2018-09-25 Twi Biotechnology Inc diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074079A1 (en) 2004-10-04 2006-04-06 Leopoldo Espinosa Abdala Solid pharmaceutical formulations comprising Diacereine and Meloxicam
JP2010506936A (ja) 2006-10-20 2010-03-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 痛風および偽痛風を治療するための、ｉｌ−１アンタゴニストの使用
US20100150938A1 (en) 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US20120232044A1 (en) 2011-03-11 2012-09-13 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
PL2224914T3 (pl) * 2007-09-14 2015-11-30 Wockhardt Ltd Kompozycje diacereiny
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074079A1 (en) 2004-10-04 2006-04-06 Leopoldo Espinosa Abdala Solid pharmaceutical formulations comprising Diacereine and Meloxicam
JP2010506936A (ja) 2006-10-20 2010-03-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 痛風および偽痛風を治療するための、ｉｌ−１アンタゴニストの使用
US20100150938A1 (en) 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US20120232044A1 (en) 2011-03-11 2012-09-13 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709754B2 (en) 2016-04-08 2020-07-14 Korea Institute Of Oriental Medicine Composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising extract of Alpinia oxyphylla as effective ingredient

Also Published As

Publication number Publication date
AR085662A1 (es) 2013-10-16
KR20140019795A (ko) 2014-02-17
US20120232044A1 (en) 2012-09-13
JP2014507476A (ja) 2014-03-27
TWI505827B (zh) 2015-11-01
PT2683372T (pt) 2017-10-25
MX2013010384A (es) 2013-10-07
IL228030A0 (en) 2013-09-30
ES2634562T3 (es) 2017-09-28
IL228030B (en) 2018-01-31
TW201249432A (en) 2012-12-16
JP6012639B2 (ja) 2016-10-25
CN103429236B (zh) 2016-09-21
CA2829101C (en) 2019-08-20
NZ614486A (en) 2014-11-28
CN103429236A (zh) 2013-12-04
AU2012229443A1 (en) 2013-09-12
BR112013022332A2 (pt) 2017-05-30
WO2012125359A1 (en) 2012-09-20
RU2013145498A (ru) 2015-04-20
US8865689B2 (en) 2014-10-21
EP2683372A1 (en) 2014-01-15
MX350666B (es) 2017-09-12
CA2829101A1 (en) 2012-09-20
EP2683372A4 (en) 2014-08-06
AU2012229443B2 (en) 2017-03-02
EP2683372B1 (en) 2017-07-12
RU2603050C2 (ru) 2016-11-20

Similar Documents

Publication Publication Date Title
KR101567885B1 (ko) 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물
Daskalopoulou et al. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia
ES2431300T3 (es) Composición farmacéutica que contiene (1S)-1,5-anhidro-1-[5-(4-etoxibencil)-2-metoxi-4-metilfenil]-1-tio-D-glucitol y metformina y utilizaciones de la misma en el tratamiento de la diabetes
CN101505594A (zh) 代谢紊乱的组合治疗
JP2011515349A5 (enExample)
CA2755072A1 (en) Combination therapies for treating metabolic disorders
CN108882744B (zh) 含有益智提取物的组合物以及益智提取物的用途
JP2007525440A6 (ja) アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ
JP2007525440A (ja) アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ
RU2012110592A (ru) Соединения и способ снижения мочевой кислоты
EP4512397A2 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
TW202143956A (zh) 用於糖尿病及其併發症治療的聯合用藥及其藥物組合物
CA2883118A1 (en) Combinations of sglt 2 inhibitors and antihypertensive drugs
AU2020201980A1 (en) Combination of FXR agonists
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
NZ614486B2 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN115607588A (zh) 一种标本兼治抗痛风的芹槐提取物与非布司他药物组合物及其用途
CA3104916C (en) Pharmaceutical composition for preventing diabetes and use thereof
KR101086040B1 (ko) 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
WO2008042773A2 (en) Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders
CN112755192A (zh) 双环醇类化合物在制备用于预防或治疗动脉粥样硬化疾病的药物中的应用和药物组合物
WO2008127893A1 (en) Niacin-based pharmaceutical compositions
RU2008121841A (ru) Фармацевтическая комбинация таурина, тиоктовой кислоты и микронизированной флавоноидной фракции, фармацевтическая композиция, ее содержащая, и способ лечения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20181023

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20201105

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20201105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000